Elicio Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 1.69 USD (Oct 30, 2026, 3:05 PM EDT) · Market cap 44.42M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targe...